Multi-institutional phase 2 clinical and pharmacogenomic trial of tipifarnib plus etoposide for elderly adults with newly diagnosed acute myelogenous leukemia

Tipifarnib (T) exhibits modest activity in elderly adults with newly diagnosed acute myelogenous leukemia (AML). Based on preclinical synergy, a phase 1 trial of T plus etoposide (E) yielded 25% complete remission (CR). We selected 2 comparable dose levels for a randomized phase 2 trial in 84 adults...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Karp, Judith E., Vener, Tatiana I., Raponi, Mitch, Ritchie, Ellen K., Smith, B. Douglas, Gore, Steven D., Morris, Lawrence E., Feldman, Eric J., Greer, Jacqueline M., Malek, Sami, Carraway, Hetty E., Ironside, Valerie, Galkin, Steven, Levis, Mark J., McDevitt, Michael A., Roboz, Gail R., Gocke, Christopher D., Derecho, Carlo, Palma, John, Wang, Yixin, Kaufmann, Scott H., Wright, John J., Garret-Mayer, Elizabeth
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: American Society of Hematology 2012
Aiheet:
Clinical Trials and Observations
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3251236/
https://ncbi.nlm.nih.gov/pubmed/22001391
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2011-08-370825
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia